One‐week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies
暂无分享,去创建一个
K. Lai | H. Xia | K. Lai | S. Lam | H. Xia | Q. Gu | W. H. Wang | W. M. Wong | H. Lu | S. Xiao | B. Wong | F. Fung | Yan Yin | Y. Yin | W. Wong | B. Wong | Qing Gu | S. D. Xiao | S. Lam
[1] C. Soussy,et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy , 2001, Alimentary pharmacology & therapeutics.
[2] R. Malekzadeh,et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate , 2001, Alimentary pharmacology & therapeutics.
[3] M. Yuen,et al. One‐week ranitidine bismuth citrate‐based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance , 2001, Alimentary pharmacology & therapeutics.
[4] Sd Xiao,et al. A multicentre study on eradication of Helicobacter pylori using four 1‐week triple therapies in China , 2001, Alimentary pharmacology & therapeutics.
[5] N. Leung. Working towards a real cure for patients with small hepatocellular carcinoma , 2001, Journal of gastroenterology and hepatology.
[6] G. Tytgat,et al. A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine , 2000, Alimentary pharmacology & therapeutics.
[7] W. Wong,et al. 13C‐urea breath test without a test meal is highly accurate for the detection of Helicobacter pylori infection in Chinese , 2000, Alimentary pharmacology & therapeutics.
[8] Mukhopadhyay,et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong , 2000, Alimentary pharmacology & therapeutics.
[9] K. Chu,et al. One-week ranitidine bismuth citrate-based low dose clarithromycin triple therapy is superior to omeprazole-based regime for the eradication of Helicobacter pylori (H. Pylori) in Hong Kong with high prevalence of metronidazole resistance , 2000 .
[10] Vahedi,et al. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease , 2000, Alimentary pharmacology & therapeutics.
[11] L. van Doorn,et al. Importance of Helicobacter pylori cagA and vacAstatus for the efficacy of antibiotic treatment , 2000, Gut.
[12] Hoffman,et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States , 2000, Alimentary pharmacology & therapeutics.
[13] F. Gomollón,et al. Quadruple Therapy Is Effective for Eradicating Helicobacter pylori After Failure of Triple Proton‐Pump Inhibitor–Based Therapy: A Detailed, Prospective Analysis of 21 Consecutive Cases , 1999, Helicobacter.
[14] R. Spiller,et al. Antimicrobial Susceptibility Testing ofHelicobacter pylori in a Large Multicenter Trial: the MACH 2 Study , 1999, Antimicrobial Agents and Chemotherapy.
[15] Gisbert,et al. Seven‐day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole , 1999, Alimentary pharmacology & therapeutics.
[16] J. Gisbert,et al. Re-treatment after Helicobacter pylori eradication failure. , 1999, European journal of gastroenterology & hepatology.
[17] Hyde,et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor‐based triple therapy fails in clinical practice , 1999, Alimentary pharmacology & therapeutics.
[18] Xiao,et al. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week , 1999, Alimentary pharmacology & therapeutics.
[19] Xiao,et al. Furazolidone‐containing short‐term triple therapies are effective in the treatment of Helicobacter pylori infection , 1999, Alimentary pharmacology & therapeutics.
[20] Lau,et al. Triple therapy for Helicobacter pylori eradication is more effective than long‐term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long‐term follow‐up study , 1999, Alimentary pharmacology & therapeutics.
[21] R. Spiller,et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. , 1999, Gastroenterology.
[22] S. Lam,et al. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection , 1998, Journal of gastroenterology and hepatology.
[23] C. O'Morain,et al. Metronidazole Resistance Reduces Efficacy of Triple Therapy and Leads to Secondary Clarithromycin Resistance , 1997, Digestive Diseases and Sciences.
[24] Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. , 1997, Gut.
[25] B. C. Wong,et al. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. , 1996, Gut.
[26] R. Hopkins,et al. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. , 1996, Gastroenterology.
[27] Jerome J. Schentag,et al. In vitro selection of resistant Helicobacter pylori , 1990, Antimicrobial Agents and Chemotherapy.
[28] G. Tytgat,et al. Cure of duodenal ulcer associated with eradication of Helicobacter pylori , 1990, The Lancet.
[29] B. Marshall,et al. PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI , 1988, The Lancet.
[30] D. Forman,et al. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. , 1997, Gut.
[31] S. Lam,et al. Prevalence of metronidazole resistant Helicobacter pylori (Hp) strains among the Chinese peptic ulcer disease patients and normals in Hong Kong , 1995 .